SCHEMBL18152339

SCHEMBL18152339

NC(=O)c1ccc(CBr)c(-c2ccc(F)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.48
CHEK2 O96017 3/20 0.43
AR P10275 2/20 0.43
PTPN1 P18031 1/20 0.42
MAP4K4 O95819 1/20 0.42
PARP1 P09874 1/20 0.41
MAOB P27338 1/20 0.40
PARP10 Q53GL7 1/20 0.40
BCL2L1 Q07817 1/20 0.40
BAD Q92934 1/20 0.40
GRM2 Q14416 2/20 0.39
GAK O14976 1/20 0.39
PDGFRB P09619 1/20 0.39
KIT P10721 1/20 0.39
FLT3 P36888 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
MARK1 Q9P0L2 1/20 0.39
STK17A Q9UEE5 1/20 0.39
DPP4 P27487 1/20 0.38
IKBKB O14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18152459 0.85 PTGS1 (0.48) PTGS1CHEK2ARMAP4K4PARP1
SCHEMBL18152401 0.82 PTGS1 (0.46) PTGS1CHEK2ARMAP4K4PARP1
SCHEMBL18152509 0.81 PTGS1 (0.45) PTGS1CHEK2ARPARP1MAOB
SCHEMBL20021930 0.80 MPL (0.47) PTGS1CHEK2AR
SCHEMBL18152340 0.78 PTGS1 (0.42) PTGS1CHEK2ARMAP4K4PARP1
SCHEMBL20300366 0.77 PARP1 (0.44) ARPTPN1PARP1MAOBPARP10
SCHEMBL18165201 0.76 MAPK14 (0.52) PTGS1CHEK2ARPARP1BCL2L1
SCHEMBL30131529 0.76 PTGS1 (0.54) PTGS1CHEK2ARMAP4K4PARP1
SCHEMBL18152554 0.75 PTGS1 (0.40) PTGS1CHEK2ARMAP4K4PARP1
SCHEMBL28203139 0.74 PTGS1 (0.53) PTGS1CHEK2MAP4K4PARP1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2018-04-05 US disclosed
WO-2016168524-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2016-10-20 WO disclosed
WO-2016168524-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS BCL9, BCL9L, BCL3 PTGS1 4219/4885CHEK2 3638/4885AR 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.